ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyReferences
Eosinophilic dermatosis of hematologic malignancy
Other Resources UpToDate PubMed

Eosinophilic dermatosis of hematologic malignancy

Contributors: Layal Antoury, Susan Burgin MD
Other Resources UpToDate PubMed

Synopsis

Eosinophilic dermatosis of hematologic malignancy (EDHM), also known as insect bite-like persistent hypersensitivity reaction, is a rare eosinophilic eruption associated with hematoproliferative diseases. Clinical presentations vary, ranging from erythematous or urticarial papules, plaques, or nodules, to vesicles and bullae. Lesions have a tendency to persist over long periods and recur, and they may be accompanied by significant pruritus.

Although clinical and histological features simulate insect bites, the condition is currently regarded as a paraneoplastic cutaneous reaction pattern likely mediated by interleukin (IL)-4 and IL-5.

EDHM is most commonly associated with chronic lymphocytic leukemia, affecting up to 7% of patients in some studies. It has also been reported in patients with myelofibrosis, acute myelomonocytic leukemia, acute lymphocytic leukemia, mantle cell lymphoma, large cell lymphoma, and myeloma. EDHM can precede, occur concurrently, or appear after the cancer diagnosis. EDHM is a disease of adults. The youngest reported patient with EDHM was 21 years of age.

Codes

ICD10CM:
D72.1 – Eosinophilia
L99 – Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

SNOMEDCT:
95320005 – Disorder of skin

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

References

Subscription Required

Last Reviewed: 08/25/2020
Last Updated: 08/25/2020
Copyright © 2020 VisualDx®. All rights reserved.
Eosinophilic dermatosis of hematologic malignancy
Print  
Eosinophilic dermatosis of hematologic malignancy
Copyright © 2020 VisualDx®. All rights reserved.